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Abstract
Pancreatic cancer (PanCa) is a major cause of cancer-related death due to limited therapeutic 
options. As pancreatic tumors are highly desmoplastic, they prevent appropriate uptake of 
therapeutic payloads. Thus, our objective is to develop a next-generation nanoparticle system for 
treating PanCa. We generated a multi-layered Pluronic F127 and polyvinyl alcohol stabilized and 
poly-L-lysine coated paclitaxel loaded poly(lactic-co-glycolic acid) nanoparticle formulation 
(PPNPs). This formulation exhibited optimal size (~160 nm) and negative Zeta potential (−6.02 
mV), efficient lipid raft mediated internalization, pronounced inhibition in growth and metastasis 
in vitro, and in chemo-naive and chemo-exposed orthotopic xenograft mouse models. 
Additionally, PPNPs altered nanomechanical properties of PanCa cells as suggested by the 
increased elastic modulus in nanoindentation analyses. Immunohistochemistry of orthotopic 
tumors demonstrated decreased expression of tumorigenic and metastasis associated proteins 
(ki67, vimentin and slug) in PPNPs treated mice. These results suggest that PPNPs represent a 
viable and robust platform for (PanCa).
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In this study, we demonstrate the therapeutic efficacy of a novel PLGA-PTX nanoformulation 
(PPNPs). This system shows efficacy both in vitro and in vivo. Specifically, nanoindentation 
studies show an increased rigidity of PPNPs-treated pancreatic cancer cells, indicating reduced 
metastatic potential as confirmed with additional results herein (proliferation, colony formation, 
invasion, migration, cell cycle arrest, apoptosis induction). In vivo results indicate successful 
reduction in tumor growth, metastasis, and EMT markers in chemo-naïve and chemo-exposed 
orthotopic xenograft mice, suggesting that PPNPs may be a next-generation paclitaxel 




Pancreatic cancer (PanCa) ranks as the fourth highest cause of cancer-related mortality in the 
US mainly due to difficulties in detection and chemoresistance(1). Hoff et al recently 
showed that gemcitabine with Abraxane (albumin-bound paclitaxel) only led to 
approximately 8.5 months survival increase as compared to 6.7 months for gemcitabine 
alone (2). Many new drugs and combinations have led to poor tolerance, low half-life, low 
cellular uptake, and high systemic toxicity (3–6). Such options largely fail by Phase II or III 
trials, causing huge financial burdens. PanCa exhibits several features leading to 
disorganized, leaky, nonfunctional vasculature (7–9), dense stroma (10), and deregulated 
cellular transport proteins (11). This leads to ineffective drug delivery and chemoresistance 
via high interstitial fluid pressure (12), stopping drugs from reaching vasculature to the 
extracellular compartment.
Paclitaxel (PTX), a natural product derived from Pacific Yew trees, is a second-line therapy 
in PanCa (13). PTX has shown therapeutic efficacy in many cancer types including PanCa 
(14). More recently, Abraxane (albumin-bound paclitaxel) has improved the efficacy of 
gemcitabine; since PTX reduced levels of cytidine deaminase (an enzyme responsible for 
gemcitabine degradation), allowing for greater concentrations of intracellular 
gemcitabine(15). Studies have shown that PTX alters TME and desmoplasia to improve 
GEM uptake in PanCa (2). In this study, we developed a next-generation PLGA-PTX nano-
formulation (PPNPs) by incorporating Pluronic F127 to improve PTX therapy in PanCa 
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patients. Poly(lactic-co-glycolic acid) (PLGA) is an FDA-approved biodegradable and 
biocompatible polymer employed for drug delivery applications including anti-cancer drug 
delivery (16, 17) and Pluronic F127 has shown potential in the reversing drug resistance (18, 
19). Herein, we have shown that PPNPs inhibit PanCa growth and metastasis in chemo-naïve 
and chemo-exposed orthotopic xenograft mouse models. Moreover, nanoindentation 
analyses demonstrate altered nanomechanical properties of PanCa cells by PPNPs treatment.
Methods
Cell culture
PanCa cells (AsPCl, Panc-1, MIA PaCa-2 and HPAF-II) were purchased from the ATCC and 
were grown according to manufacturer’s protocol.
PLGA-PTX nanoparticle (PPNPs) preparation
PPNPs were generated using a modified procedure as described previously (20). First, an 
aqueous solution of 1% PVA (Sigma, P8136) was made. Then, a solution of PLGA (Lactel 
Polymers, B6010–4) in acetone (90 mg/5ml) was made in duplicate (PLGA control and 
PPNPs). Once both solutions were dissolved, 10 mg of PTX (Advanced ChemBlocks, 
F-4194) was added to one PLGA-acetone mixture to generate PPNPs. The PLGA-acetone 
mixture was added dropwise to the PVA solution then mixed overnight at 800 rpm while 
loosely covered in foil to allow for acetone evaporation. The next day, 5 mg/ml of PLL 
(Sigma, P2636) and F127 (Sigma, P2443) was made in Milli-Q water and was added 
dropwise to each beaker (2 ml each). This solution was mixed for seven hrs, then the volume 
was brought to 20 ml using Milli-Q. Samples were aliquoted into 1.5 ml tubes and stored at 
−20°C. One tube of control and loaded particles were taken and briefly sonicated using a 
probe sonicator (MISONIX Inc.) to ensure proper homogeneity for DLS analysis.
Particles size and zeta potential
Size, distribution and zeta potential of PPNPs were determined using DLS (ZetaSizer Nano 
ZS, Malvern Instruments, Malvern, UK). Briefly, 10 μl. of the particles was mixed into 990 
μl of the dispersant (PBS, cell culture media, or 10% filtered human serum) and run using 
DLS measurements. Both particle size and zeta potential were collected in all three media.
HPLC-based drug loading assay
One ml of PPNPs aliquot was placed at −80°C for 4 hrs with loosely closed lids. The 
particles were lyophilized using a FreeZone 2.5 (LabConco) lyophilizer system and were 
mixed with 1 ml of acetonitrile with constant shaking for 24 hrs, then sonicated in a water 
bath for 2–3 hrs. The vials were then centrifuged at 10,000 rpm for 15 minutes and 500 μl of 
supernatant was collected for PTX loading by HPLC analysis. A mobile phase of 50/50 
acetonitrile/water was used with a flow rate of 1 ml/minute, and PTX loading was 
determined at wavelength of 227 nm. The samples were run through a 50×2.1 mm column 
(ThermoFisher) with a 5 minute run time. A standard curve of PTX was generated using 
varying concentrations (1–1000 μg/ml). Encapsulation efficiency was calculated by taking 
the amount of drug determined to be held in the particles divided by the total amount of drug 
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added, and drug loading was calculated by dividing the encapsulated drug by the total 
nanoparticle weight.
Fourier Transform infra-red (FT-IR) and X-ray diffraction
FT-IR spectra of PTX, PLGA, and PPNPs were obtained using Fourier Transform infra-red 
(FT-IR) microscope (Smiths Detection, Danbury, CT). The spectra data, 4,000–1000 cm−1, 
was acquired at a resolution of 4 cm−1 for 32 scans by placing PTX or lyophilized PLGA/
PPNPs powder on the attenuated total reflection objective. The X-ray diffractograms 
measurements were acquired using Rigaku D/Max-B diffractometer at a scanning speed of 
1° per minute (Rigaku Americas Corp, Woodlands, TX).
PPNPs characterization by atomic force microscopy (AFM)
AFM studies were conducted to determine the physical properties of PLGA and PPNPs. 
Nanoparticles were diluted in Milli-Q (1:1000) and placed on a glass slide to air dry 
overnight. AFM images were taken (2×2 square microns) using a ScanAsyst Air probe. To 
assess the physical characteristics of these nanoparticles, an RTESPA-300 probe was used 
(nominal spring constant 40N/m, tip radius ~8nm). The probe was calibrated by engaging 
onto a clean glass slide and ramping to calculate the deflection sensitivity. The spring 
constant was then calculated using the Sader method. A 2×2 square micron region was 
selected, and a force scan was conducted (128×128 pixels, ramp speed 60 Hz). Ten particles 
were selected at random from multiple scans and their modulus and adhesion data were 
analyzed and averaged.
Cellular uptake studies
Six-well plates were seeded (200,000/well). Once 75% confluent, treatment groups (PLGA 
or PPNPs with additional coumarin-6) were added for three hrs (2.5, 5, and 10 nM). The 
cells were rinsed with PBS and phenol red-free media was added. Microscopic images were 
taken to observe fluorescence of intracellular coumarin-6. Then cells were collected in PBS 
and run on the flow cytometer using channel FL1. Plates were seeded in the same way for 
uptake studies: HPAF-II and Panc-1 were treated with pathway inhibitors (genistein, 
amiloride, nocodazole, chlorpromazine, MBCD, incubation at 4°C) for one hr. The media 
was replaced and treated with coumarin-6 labelled PPNPs for one hr. The cells were then 
washed with PBS, collected in phenol red-free media, and analyzed for internalized 
coumarin-6 fluorescence in PanCa cells by flow cytometry using channel FL1.
MTT assay
The effect of cell proliferation on PanCa cells was assessed by MTT assay as described 
previously (21). For this experiment, at ~75% confluency, cells were treated with PPNPs 
(1.25–40 nM). for 48 hrs. Effect of PPNPs on cell proliferation was also determined by real 
time xCELLigence system as described previously (21).
Colony formation assay
The cells were seeded into 12-well plates (300/well) and attached overnight. Treatment was 
initiated once 50-cell colonies were seen. After two weeks, the media was aspirated, and 
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colonies were fixed using cold methanol for 2–3 minutes. Cells were stained using 0.5% 
crystal violet and the colonies were counted.
Cell cycle analysis
A six-well plate was seeded (300,000/well) and attached overnight then treated with PPNPs 
for 24 hrs. Cells were fixed using cold 70% EtOH with gentle vortexing, then kept at 4°C for 
at least one hr, centrifuged, washed with PBS and re-suspended in 1 ml of Telford reagent 
with RNAse. The cells were then incubated in the dark for 4 hrs at 4°C, then run using a BD 
Accuri Flow Cytometer using channel FL2.
Apoptosis assessment by flow cytometry
Cells (300,000/well) were seeded in six well plates, attached overnight, then treated for 48 
hrs. Cells were washed with PBS and diluted in Annexin-V binding buffer (1×106 cells/ml). 
One sample was left unstained as a gate control, the other samples were treated with 5 μl 
Annexin-V and 7-AAD and incubated for 20 minutes in the dark at room temperature and 
cells were analyzed using channels FL2 and FL3.
Western blot analysis
Cells were seeded into 150 mm dishes and grown to 75% confluency. PPNPs treatment was 
then given for 48 hrs. Cell lysates were prepared and quantified using the Bradford assay. 
Forty micrograms of protein were added to a 10% SDS-PAGE gel. The protein was then 
transferred to a PVDF membrane and blocked in 5% milk for 30 minutes at room 
temperature. Blots were incubated in primary antibody overnight at 4°C, followed by HRP-
conjugated secondary antibody for 1 hr and developed with ECL reagent using a UVP gel 
documentation system.
Chemoinvasion assay
Cell invasion assays were conducted to determine if PPNPs could inhibit invasive potential 
of PanCa cells using our previously published protocol (21). Real-time assays on 
exCELLigence were also conducted (21).
Cell migration assay
Cell migration assays were performed using Boyden chambers (BD Biosciences) according 
to the manufacturer’s protocol as described previously(21). Effect of PPNPs on migration 
assay was also performed using the xCELLigence system as previously mentioned (21).
Nanoindentation and AFM imaging analysis
Cells were seeded in 60 mm dishes (500,000 cells) and attached overnight then treated with 
PLGA and PPNPs (10 nM) for 24 hrs. The cells were washed with PBS three times and 
fresh media was added. The dish was taken to the AFM and placed on a heated stage (37°C) 
and equilibrated for 15 minutes. Using PFQNM-LC probes, the deflection sensitivity was 
calculated via thermal tune. High-resolution images (256×256 resolution, 0.3Hz, 100 pN 
peak force set point) were taken to assess cellular morphology. A force curve was then 
generated on the center of a cell to confirm contact, then a force volume scan was conducted 
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(128×128 resolution, 512 ramps per pixel, 15Hz ramp rate) to generate a force map of the 
entire cell. After collecting data on multiple cells, the average physical parameters (modulus 
and adhesion) were calculated at the nuclear, cytoplasmic, and peripheral regions and 
averaged.
Xenograft study
Six-week-old athymic nude mice were purchased from Jackson Laboratory, housed under 
pathogen-free environment with a 12-h light/12-h dark schedule, and fed an autoclaved diet 
and water ad libitum. This study was conducted using protocols approved by UTHSC 
Institutional Animal Care and Use Committee (IACUC ID #16–049.0-C). Sixteen mice were 
used to establish orthotopic xenograft tumors with human PanCa cells (HPAF-II-luciferase). 
Cells were harvested from subconfluent cultures and washed once in serum-free medium 
and suspended in HBSS. Only suspensions with >90% viability were used. The pancreas of 
anaesthetized mice was exposed through a midline laparotomy incision and by splenic 
retraction. Cells (2.0×106) in 50 μl of HBSS containing 10% (v/v) Matrigel was injected into 
pancreatic parenchyma. Incisions were closed by suture followed by clipping. Ten days later, 
mice were imaged via IVIS Spectrum bioluminescence scanner (PerkinElmer, Waltham, 
MA): Five minutes prior, 100 μl of D-luciferin substrate (30 mg/ml) was injected i.p. 
Quantification was conducted using vendor software (Living Image® 4.0) by measuring the 
total photons over the pancreatic region and the average photon flux within regions-of-
interest (ROI) represented as photons/second/cm2/sr (sr denotes steradian). Mice with equal 
tumor volumes were divided into control (n=6) and PPNPs (n=6) groups and rest (n=4) were 
excluded. For dose-escalation studies, we first administered PPNPs (1 mg/kg body weight; 
twice a week for two weeks, then 10 mg/kg twice a week for three weeks). Control mice 
were administered unloaded PLGA. Mice were imaged for tumor growth at 10, 21, 30, and 
37 days. At the time of sacrifice, tumors were removed, fixed in formalin, embedded in 
paraffin, and sliced into 5 mm sections for further analysis. To determine the effect of 
PPNPs on PanCa metastasis, distant organs (liver, lungs and lymph nodes) were excised, 
imaged, and analyzed for histopathology. We further evaluated the effect of PPNPs on PTX 
resistance. In this experiment, HPAF-II-luciferase labelled cells derived orthotopic xenograft 
tumor mice (n=6) were treated with PTX (10 mg/kg) i.p twice weekly for 5 weeks. At six 
weeks, half of the mice received PPNPs (10 mg/kg) i.p and the other half received PLGA. 
Tumor growth in these mice was monitored by bioluminescence imaging as described 
previously (22).
Immunohistochemistry analysis
Immunohistochemistry (IHC) was performed to determine the expression of ki67, vimentin, 
and slug in excised tumors of control and PPNPs treated mice. Our IHC protocol can be seen 
in previously published data (21).
Statistical analysis
Statistical analyses were performed using unpaired two-tailed Student t tests employed to 
assess the statistical significance between the control and PPNPs treated groups. P values < 
0.05 were considered significant.
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Optimization of PPNPs formulation for PanCa therapeutics
Our nano-formulation (Fig. 1A) has several unique properties: (i) the FDA-approved PLGA 
core is capable of storage and controlled release of PTX; (ii) PVA, a widely used NP 
stabilizer, supports stability for over 6 month(s) and avoids non-specific adsorption of serum 
proteins in vivo; (iii) PLL promotes cellular internalization and is less toxic compared to 
other polycationic polymers; (iv) amine functional groups (PLL) assist in antibody 
conjugation, and (v) F127 polymer has shown potential in overcoming drug resistance (19, 
23). DLS characterization yielded an average size of 140 nm for PLGA and 160 nm for 
PPNPs (Fig. 1B) and exhibited moderately negative zeta potential (Fig. 1C). To confirm 
PTX uptake in PPNPs, we performed FT-IR and XRD analyses. In the FT-IR spectrum of 
PLGA (Fig. 1E, black line), the intense peaks were found at 1000 cm−1, 1281 cm−1, and 
1010 cm−1 due to C=O stretching of ester, C-O stretching of ester, and glycosidic (C–O–
C/C–C/C–O) stretch vibrations. District PTX FT-IR and XRD peaks were noticed (Fig. 
1D/E, red line), but after encapsulation these sharp peaks disappeared in PPNPs (Fig. 1D,E, 
green line), which closely resembled control PLGA (Fig. 1D,E, black line). XRD analysis 
showed similar results – PTX crystalline peaks disappeared upon encapsulation in PPNPs 
(Fig. 1D/E).
Characterization of PPNPs by atomic force microscopy
With AFM imaging, particles were noted to be somewhat smaller in air (between 90–120 
nm). This may be due to swelling in a liquid environment seen with DLS (Fig. 1Fi–ii). For 
both PLGA and PPNPs, there was no significant difference in the modulus. However, the 
effect of the other polymers in this particle system are not yet fully understood.
PPNPs internalize in PanCa cells primarily through lipid-raft mediated endocytosis
Qualitative analysis of coumarin-6 loaded nanoparticles showed a dose-dependent increase 
in PPNPs uptake. The uptake was noticeably higher in Panc-1 compared to HPAF-II (Fig. 
2A–B). Results revealed a strong uptake by both HPAF-II (Fig. 2Aii) and Panc-1 cells (Fig. 
2Bii) which was inhibited by MBCD. However, Panc-1 cells showed energy-dependent 
uptake, while HPAF-II cells showed energy-independent uptake (Fig. 2Aiii, Biii). Although 
this indicates overall differences, both cell lines demonstrated similar inhibition of lipid raft 
mediated endocytosis (24).
PPNPs effectively inhibits growth, invasion and migratory potential of PanCa cells
PPNPs inhibited cell viability of PanCa cells in a dose-dependent (1.25–40 nM) manner 
(Fig. 3A). IC50 of PPNPs in Panc-1 and MIA PaCa-2 cells was approximately 5 nM, while 
IC50 was 20 nM in HPAF-II cells at 48 hrs. A similar effect was also observed using 
xCELLigence assay (Fig. 3B) that monitors real-time inhibition of cell growth as described 
(21). PPNPs significantly (P<0.01) inhibited colony formation in all three PanCa cell lines 
(Panc-1 AsPC1 and MIA PaCa-2) at 2 nM (Figure 3, Ci–ii). We observed a more profound 
effects of PPNPs as compared to free PTX as shown in revised Supplementary Figure 4A–D. 
PPNPs have shown improved growth inhibitory effects on PanCa cells compared to free 
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PTX. Moreover, PPNPs showed almost similar effects as abraxane in xCELLigence 
experiment in term of PanCa cells proliferation. In colony formation assays, PPNPs were 
shown to have a significantly higher therapeutic effect on GEM-resistant cells (Panc-1), 
however this effect was not significant in other non-Gemcitabine resistant cells. Overall, 
these data suggest that PPNPs nanoformulation has a superior efficacy compared to free 
PTX. PPNPs also dose-dependently (1.25–5.0 nM) inhibited invasion (Fig. 3D) and 
migration (Fig. 3E) of Panc-1 cells. This was further demonstrated by real-time inhibition of 
migration using AsPC1 cells with xCELLigence assay (Fig. 3F).
PPNPs induce biophysical changes in PanCa cells as measured by nanoindentation 
analysis
After imaging the cells, differences were noted in the morphology – specifically, a notable 
shrinkage of the outer membrane (Fig. 4 Ai–ii, Bi–ii). After conducting nanoindentation 
analyses, the overall modulus was shown to increase in both cell lines (Fig. 4 Aiii, Biii). 
PPNPs treatment of AsPC1 for 24 hrs showed an increased modulus at the cytoplasmic and 
peripheral regions. Interestingly, the membrane adhesion was generally reduced with PPNPs 
treatment (Fig. 4 Aiv). Although cell modulus is a widely studied biophysical parameter, 
less evidence exists to explain the implications of reduced adhesion from a biochemical 
standpoint. The expected trends were also seen in Panc-1 (Fig. 4B), including an increased 
modulus across the cell. These results agree with the consensus that cancerous cells have a 
lower modulus compared to their healthy counterparts (25–27).
PPNPs arrests cell cycle in the G2/M phase and induces apoptosis in PanCa cells
PPNPs dose-dependently arrested cell cycle in G2/M phase (Fig. 5A). It is well documented 
that G2/M cell cycle arrest leads to the induction of apoptosis (28). Our data also shows that 
PPNPs (5–20 nM) of PanCa exhibited a dose-dependent increase in early-phase apoptosis 
(Fig. 5B). PPNPs dose-dependently increased the PARP cleavage in both Panc-1 and HPAF-
II (Fig. 5C), which indicative of early apoptosis biomarker (29).
PPNPs suppresses pancreatic tumor growth and metastasis in chemo-naïve and chemo-
exposed orthotopic xenograft mice
In our in vivo studies, tumor volume was not affected at initial dosing of 1 mg/kg (Fig. 6 
B,C). However, 10 mg/kg dosing showed a significant (P<0.01) difference from Day 30 
onwards (Fig. 6 B,C). Bioluminescence results of excised pancreas demonstrated a 
significant (P<0.05) decrease of intensity in PPNPs treated mice (Fig. 6D). PPNPs treatment 
showed a significant (P<0.01) decrease in tumor weight compared to vehicle (Fig. 6E). 
These results agreed with the bioluminescence findings from excised pancreatic tumors. 
Histopathological analysis of excised tumor showed small necrotic areas in PPNPs treated 
mice (Fig. 6G). Immunohistochemistry results showed a decrease in ki67 in PPNPs treated 
mice (Fig. 6H). No apparent organ toxicity (heart and kidneys) was observed in PPNPs 
treated mice as determined by histopathological analysis (Supplementary Fig. 1). All control 
mice showed a high incidence of pancreatic metastasis in lymph nodes, liver, and lungs, 
which was significantly reduced with PPNPs (Fig.6F). Histopathological analysis results 
further confirmed decreased metastases in PPNPs treated mice – with only minimal foci in 
the lungs (Fig.7A). Immunohistochemistry results illustrated inhibition of EMT markers 
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(vimentin and slug) in excised tumors of PPNPs treated mice (Fig.7B). PPNPs 
administration (10 mg/kg) significantly (P<0.05) inhibited tumor growth, even in pre-
exposed mice as determined by significant (P<0.05) inhibition of bioluminescence counts 
(Fig. 7 E,F) and decrease in excised tumor weight (Fig. 7G).
Discussion
Pancreatic cancer remains one of the deadliest cancers in the United States due to limited 
therapeutic options (30). Only 10–20% of patients diagnosed with localized disease are 
candidates for surgical resection; moreover, post-operative disease recurrence is very 
common (31). Nanoparticles (NPs) are known to preferentially accumulate in tumor tissue 
due to leaky vasculature, mainly via Enhanced Permeation and Retention (EPR) effect (32, 
33). Abraxane® (albumin-bound paclitaxel) has been widely used in clinic for the treating 
various cancers, including PanCa (34–36), indicating that nano-drug delivery systems have 
superior therapeutic outcomes over free drug. In addition, nano-scale drug delivery has been 
shown by various studies to improve on-target uptake of drug, which can overcome drug 
resistance and lead to overall reduction in the administered dose and systemic toxicity (37). 
Therefore, the main objective of this study was to develop a new nano-formulation of PTX. 
Herein, we developed a unique formulation (PPNPs) using F127 polymer and optimized it 
against PanCa using in vitro and in vivo model systems.
Our first step was to generate and characterize this formulation. DLS characterization 
yielded an average size of 160 nm and exhibited moderately negative zeta potential – both 
ideal for nano-scale drug delivery. In the FT-IR and XRD spectra, characteristic peaks of 
PLGA were not affected by PTX loading as seen PLGA and PPNPs peak similarities. It 
should be noted however that FTIR and XRD data only represents the overall composition 
and physical state of the formulation. To determine the PTX loading in our nanoformulation, 
we used an HPLC-based method to quantify the encapsulation efficiency. Our results 
indicated an encapsulation efficiency ranging from of 72–86%, and an experimentally 
calculated drug loading of 7.4–8.7% (Supplementary Figure 2). Our AFM results indicate no 
change in the physical properties of PLGA nanoparticles after PTX encapsulation which was 
suggested by a similar modulus in PLGA and PPNPs (~ 12 GPa). These results should be 
seen as semi-quantitative because the modulus of bulk PLGA is reported around 2 GPa (38), 
but the modulus of other components (PLL, PVA and F127) are not known. Our results 
indicate differing internalization of PPNPs in Panc-1 and HPAF-II cells and was noticeably 
higher in Panc-1. However, both cells showed inhibition with MBCD treatment (lipid raft 
mediated endocytosis). (24). Further study is required to determine whether PPNPs uptake is 
cell line specific.
In this study, we established that PPNPs demonstrate anti-cancer activity against PanCa. 
MTT and colony formation assays indicate that PPNPs inhibit growth and proliferation of 
PanCa cells. It is well documented that invasion and migration represent two critical 
components of metastatic cascades (39). We observed a significant reduction in the invasive 
and migratory properties of PanCa cells treated with PPNPs in vitro. Nanoindentation 
techniques have been successfully used to investigate cancer cells recently, however the 
literature on this field is still limited. Given the ability to differentiate between healthy and 
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cancerous tissue, as well as observing the effects of various treatments can yield greater 
insights into phenotypical behaviors of cancer cells (40). Conventional nanoindentations 
have been conducted using large, spherical tips (40, 41). Although this can lead to the ability 
to quickly scan multiple cells, it also reduces the amount of data per cell. Using recently 
designed probes from Bruker custom-built for live cell applications (PFQNM-LC), we were 
able to generate force maps with significantly more data per cell, giving a greater 
understanding of the physical properties at different cellular regions. Based on our 
nanoindentation results, the overall modulus was increased in Panc-1 and AsPC1. These 
results clearly suggest that the increased rigidity caused by PPNPs will inhibit metastatic 
phenotype of PanCa cells.
It is well established that arresting cell cycle and inducing apoptosis are prime therapeutic 
targets for cancer treatment (42, 43). Various chemotherapeutics have been shown to induce 
apoptosis and arrest cell cycle (44, 45). Specifically, PTX has been shown to induce 
apoptosis and arrest the cell cycle during the G2/M phase in various cancer cells (46). Our 
results also suggest that PPNPs induce apoptosis and arrest cell cycle in G2/M phase in 
PanCa cells. This was further supported by cleavage in PARP protein, an early biomarker of 
apoptosis (29).
After accumulating significant in vitro data, we then assessed the in vivo efficacy of PPNPs. 
We used human HPAF-II-luciferase cells to generate an orthotopic xenograft mouse model. 
This model has previously been used to evaluate the therapeutic efficacy of 
chemotherapeutic agents against PanCa (47, 48). Histopathology results revealed no toxicity 
in the heart, kidney and liver of PPNPs treated mice, suggesting a 10 mg/kg dose is a safe 
dose in mice. Our imaging data of PPNPs treated mice (10 mg/kg twice a week for three 
weeks) showed a significant (P<0.01) inhibition in bioluminescence, suggesting that PPNPs 
inhibits pancreatic tumor growth. We also observed a significant (P<0.01) inhibition in the 
weight of excised tumors from PPNPs-treated mice. These findings demonstrate that PPNPs 
inhibits the progression of orthotopic xenograft tumors in athymic nude mice. In humans, 
lymph nodes, lungs, and the liver are frequent sites of PanCa metastasis. All control mice 
showed metastases in these organs with ex vivo imaging and histopathology. Our results 
showed a significant inhibition of HPAF-II-luciferase cells metastasis in PPNPs treated 
mice. PPNPs also inhibited tumor growth in PTX-exposed mice, suggesting that PPNPs are 
capable of overcoming drug resistance in PanCa.
Ki-67 is a well-known cell proliferation marker and has been used to determine the anti-
proliferative effect of therapeutic agents (49). Our data indicated a decrease of nuclear ki-67 
in PPNPs treated mice tissue. Our results show the growth inhibitory and anti-metastatic 
nature of PPNPs against human PanCa. EMT is a crucial step in metastasis (50). During 
EMT, phenotypic and molecular changes occur in cancer cells leading to loss of epithelial 
markers and an elevation of mesenchymal markers (vimentin, N-cadherin, Slug, and 
fibronectin) (51, 52). Our immunohistochemistry data of PPNPs treated mice indicated a 
decrease in vimentin and slug - indicating that PPNPs can suppress EMT in PanCa. These 
results suggest that PPNPs are a promising therapeutic modality for the treatment of PanCa 
growth and metastasis.
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We characterized the properties and therapeutic efficacy of a novel paclitaxel nanoparticle 
system (PPNPs) which has shown ideal properties for nano-scale drug delivery, as well as 
significant effects on PanCa cells in vitro. Our in vivo data also suggests that PPNPs can 
reduce tumor growth and metastatic burden in both chemo-naïve and chemo-exposed 
orthotopic xenograft mouse models. Nanoindentation analyses demonstrate that PPNPs alter 
nanomechanical properties of PanCa cells. Therefore, we are thoroughly investigating 
molecular mechanisms and targeted delivery for this formulation using clinically relevant 
mouse model systems. Overall, our results suggest the anti-cancer potential of PPNPs which 
could be used as a novel therapeutic modality for PanCa treatment.
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Figure 1: Synthesis and characterization of PLGA-PTX nanoparticles (PPNPs).
(A) Schematic overview of PPNPs synthesis. (B) DLS characterization of PLGA and 
PPNPs. (C) DLS characterization of zeta potential for PLGA and PPNPs. (D) FTIR spectra 
for free PTX, PLGA, and PPNPs. (E) XRD spectra for free PTX, PLGA, and PPNPs. (F) 
Topographical and physical analysis of PLGA and PPNPs by atomic force microscopy 
(AFM). Representative 2D and 3D images (2×2 μm2) of PLGA and PPNPs (i-ii). Modulus 
data for two separate samples (iii-iv).
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Figure 2: Cellular uptake of PPNPs in PanCa cells.
(A,B) Representative images of HPAF-II (Ai) and Panc-1 cells (Bi). Quantification of uptake 
by flow cytometry for HPAF-II (Aii) and Panc-1 (Bii). Uptake inhibitor assay for HPAF-II 
(Aiii) and Panc-1 (Biii) cells. Values in bar graphs represent mean±SE value of three sample 
in each group. *P<0.05.
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Figure 3: Effect of PPNPs on proliferation, invasion and migration of PanCa cells.
(A) Effect of PPNPs on cell viability of Panc-1, HPAF-II, and MIA PaCa-2. Values in bar 
graph represent mean ± SEM of 5 wells. (B) Real-time proliferation data using 
xCELLigence of AsPC1 cells. (C) Effect of PPNPs on clonogenic potential of PanCa cells. 
Representative colony images of control and PPNPs treated groups (i). Average colony 
counts in bar graph (ii). (D) Effect of PPNPs on invasive potential of PanCa cells. 
Representative images showing the effect of PPNPs on invasion of Panc-1 and AsPC1 cells 
through matrigel invasion assay (i). Bar graph quantification of invaded cells (ii). (E) Effect 
of PPNPs (24 hrs treatment) on migration of Panc-1 cells (i) Bar graph quantification of 
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migrated cells (ii). (F) Real-time effect of PPNPs on AsPCl cells migration as shown using 
xCELLigence system.
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Figure 4: Effect of PPNPs on physical characteristics of PanCa cells.
Nanoindentation analyses of AsPCl (A) and PanC-1 cells. Three-dimensional images of 
untreated (i) and PPNPs-treated (ii) cells. Physical data collected by nanoindentation 
showing changes in modulus (iii) and adhesion (iv) with PPNPs. (B) Analysis of Panc-1 
cells. Three-dimensional images of untreated (i) and PPNPs-treated (ii) cells. Physical data 
collected by nanoindentation shows changes in modulus (iii) and adhesion (iv) with PPNPs.
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Figure 5: Effect of PPNPs on cell cycle distribution and apoptosis of PanCa cells.
(A) Flow cytometric analysis of cell cycle arrest by PPNPs on Panc-1 and HPAF-II. 
Representative histogram images of cell cycle analysis (i). Table showing percentage of 
Panc-1 and HPAF-II cells in each phase of cell cycle after PPNPs treatment (ii). (B) Flow 
cytometric analysis of Annexin-V/7-AAD positive Panc-1 cells after treatment with PPNPs 
(i). Quantification of early and late apoptosis induction by PPNPs in Panc-1 cells (ii). (C) 
Effect of PPNPs on PARP protein cleavage in Panc-1 and HPAF-II cells as determined by 
Western blot analysis (i). Quantification of cleaved PARP to PARP proteins ratio calculated 
by the band intensity using Image J software (ii).
Massey et al. Page 20













Figure 6: Effect of PPNPs on pancreatic tumor growth in orthotopic xenograft mouse model.
(A) Schematic representation of schedule for dose escalation study of PPNPs in orthotopic 
xenograft mouse model. (B) Representative bioluminescence images of PLGA and PPNPs 
treated mice. (C) Quantification line graph of bioluminescence data in live mice. Values are 
shown as mean ± SEM with 6 mice per group. Inset images show a visual representation of 
tumor growth in indicated groups. (D) Representative pictures of ex vivo imaging of excised 
pancreatic tumor of PLGA and PPNPs treated mice. (E) Excised tumor weight of PLGA and 
PPNPs treated mice. Each dot represents one mouse. (F) Representative pictures of ex vivo 
imaging of liver, lymph nodes and lungs of PLGA and PPNPs treated mice. (G) Bar graphs 
indicating quantification of bioluminescence data for liver (i) and lymph nodes (ii) in PLGA 
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and PPNPs treated mice. (H) H&E staining of pancreatic tumor of PLGA and PPNPs treated 
mice. Black arrows indicate pancreatic tumor. Red arrows indicate pancreatic acinar cells. 
Green arrows indicate necrotic area of pancreatic tumor. (I) Representative images of 
immunohistochemical analysis of Ki-67 in PLGA and PPNPs treated mice tissue sections.
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Figure 7: Effect of PPNPs on pancreatic cancer metastasis and drug-resistant tumors.
(A) Representative H&E staining of liver and lung sections excised from PLGA and PPNPs 
treated mice. Black arrows indicate metastatic foci. (B-C) Representative 
immunohistochemical images of vimentin and slug in excised tissues. (D) Schematic 
representation of treatment schedule in orthotopic xenograft tumor-bearing mice pre-
exposed to PTX. (E) Representative bioluminescence images showing tumor density in 
PLGA and PPNPs treated mice. (F) Quantification of bioluminescence data in PLGA and 
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PPNPs treated mice. Values are shown as mean ± SEM with 3 mice per group. (G) Excised 
tumor weight in PLGA and PPNPs treated mice.
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